The Food and Drug Administration on Wednesday approved a new drug to treat patients with multiple myeloma, overruling a panel of outside cancer experts who expressed concerns about its toxicity.

The new multiple myeloma drug, called selinexor, will be marketed by Karyopharm Therapeutics (KPTI) under the brand name Xpovio.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • For Chris sake if you’re dying from MM whats the hell! Maybe the studies will lead to less toxic version so your children ‘s childrens will survive! Thank you Mr Trump for giving us the opportunity to choose our own destiny and not the FDA…

    • My understanding is that some patient deaths during the trials were attributed to the toxicity of the drug. A drug ain’t much good if it kills you before it cures you.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy